Novartis
NVS
NVS
1,270 hedge funds and large institutions have $15B invested in Novartis in 2023 Q4 according to their latest regulatory filings, with 138 funds opening new positions, 402 increasing their positions, 447 reducing their positions, and 69 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
1% less capital invested
Capital invested by funds: $15.1B → $15B (-$141M)
10% less repeat investments, than reductions
Existing positions increased: 402 | Existing positions reduced: 447
13% less funds holding in top 10
Funds holding in top 10: 16 → 14 (-2)
Holders
1,270
Holding in Top 10
14
Calls
$229M
Puts
$215M
Top Buyers
| 1 | +$728M | |
| 2 | +$81.8M | |
| 3 | +$76.9M | |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$76.3M |
| 5 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$44.5M |
Top Sellers
| 1 | -$423M | |
| 2 | -$313M | |
| 3 | -$171M | |
| 4 |
CCM
Cullen Capital Management
New York
|
-$110M |
| 5 |
Sanders Capital
West Palm Beach,
Florida
|
-$104M |